- Home
- BIIB vs RYAAY Comparison
BIIB vs RYAAY Comparison
Compare BIIB & RYAAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- RYAAY
- Stock Information
- Founded
- BIIB 1978
- RYAAY 1985
- Country
- BIIB United States
- RYAAY Ireland
- Employees
- BIIB N/A
- RYAAY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- RYAAY Air Freight/Delivery Services
- Sector
- BIIB Health Care
- RYAAY Consumer Discretionary
- Exchange
- BIIB Nasdaq
- RYAAY Nasdaq
- Market Cap
- BIIB 25.1B
- RYAAY 24.5B
- IPO Year
- BIIB 1991
- RYAAY 1997
- Fundamental
- Price
- BIIB $160.85
- RYAAY $44.53
- Analyst Decision
- BIIB Buy
- RYAAY Buy
- Analyst Count
- BIIB 25
- RYAAY 3
- Target Price
- BIIB $258.57
- RYAAY $61.87
- AVG Volume (30 Days)
- BIIB 1.7M
- RYAAY 1.4M
- Earning Date
- BIIB 10-30-2024
- RYAAY 01-27-2025
- Dividend Yield
- BIIB N/A
- RYAAY 6.44%
- EPS Growth
- BIIB 10.05
- RYAAY N/A
- EPS
- BIIB 11.06
- RYAAY 1.50
- Revenue
- BIIB $9,607,500,000.00
- RYAAY $15,124,470,215.00
- Revenue This Year
- BIIB N/A
- RYAAY $4.61
- Revenue Next Year
- BIIB N/A
- RYAAY $9.11
- P/E Ratio
- BIIB $14.54
- RYAAY $12.74
- Revenue Growth
- BIIB N/A
- RYAAY 6.49
- 52 Week Low
- BIIB $153.62
- RYAAY $36.97
- 52 Week High
- BIIB $268.30
- RYAAY $60.32
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- RYAAY 50.57
- Support Level
- BIIB $158.44
- RYAAY $42.68
- Resistance Level
- BIIB $165.29
- RYAAY $44.42
- Average True Range (ATR)
- BIIB 4.09
- RYAAY 0.77
- MACD
- BIIB 1.04
- RYAAY -0.04
- Stochastic Oscillator
- BIIB 32.51
- RYAAY 71.03
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About RYAAY Ryanair Holdings plc
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,000 flights daily across 200-plus destinations in 40-plus countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volumes, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.